Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Doris Makari"'
Autor:
Imtiaz A Samjoo, Alexandra Hall, Connie Chen, Bao-Ngoc Nguye, Meaghan Bartlett, Mary Lou Smith, Nadia Harbeck, Joseph C Cappelleri, Meghan Karuturi, Doris Makari, Lillian Shahied Arruda, Rickard Sandin, Kent Hanson, Justin Doan
Publikováno v:
Journal of Comparative Effectiveness Research, Vol 13, Iss 10 (2024)
Aim: To evaluate the impact of palbociclib treatment on health-related quality of life (HRQoL) in patients with hormone receptor-positive, human epidermal growth factor 2-negative advanced breast cancer (HR+/HER2- aBC) or metastatic breast cancer (
Externí odkaz:
https://doaj.org/article/f6f1b3a08af445aab4c5bd48f8bb6817
Autor:
Andrea Necchi, Daniel Hennessy, Juliane Manitz, Toni K. Choueiri, Noah M. Hahn, Shaad Essa Abdullah, Chen Gao, Constanze Kaiser, Ashok K. Gupta, Sandy Srinivas, Andrea B. Apolo, Jonathan E. Rosenberg, Darren Tayama, Doris Makari, Gregory R. Pond, Guru Sonpavde, Dean F. Bajorin, Matthew D. Galsky, Thomas Powles, Petros Grivas, Robert Dreicer, Guenter Niegisch
Publikováno v:
J Urol
PURPOSE: A prognostic model for overall survival of post-platinum patients with metastatic urothelial carcinoma receiving PD-1/PD-L1 inhibitors is necessary as existing models were constructed in the chemotherapy setting. MATERIALS AND METHODS: Patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ffcc9745812a737a93076ffdb93d9956
https://pubmed.ncbi.nlm.nih.gov/32552295
https://pubmed.ncbi.nlm.nih.gov/32552295
Publikováno v:
Human Vaccines & Immunotherapeutics
In July 2014, the Committee on Infectious Diseases (COID) updated their guidance on the use of palivizumab, recommending against use in preterm infants 29 to 35 weeks' gestational age (wGA). A primary data source cited to support this significant cha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::94b0f2ed4031f96f3521d5907f5216c8
https://doi.org/10.1080/21645515.2015.1115936
https://doi.org/10.1080/21645515.2015.1115936
Autor:
Charles B. Simone, Ramesh Rengan, Jingxuan Zhao, Zhiyuan Zheng, Stephen G. Chun, Brian S. Seal, Xuesong Han, Doris Makari, Helmneh M. Sineshaw, Candice Yong
Publikováno v:
Journal of Clinical Oncology. 38:2069-2069
2069 Background: Recent data suggests that a significant number of good performance, unresectable stage III non-small cell lung cancer (NSCLC) patients do not receive standard-of-care treatment, i.e. concurrent chemoradiotherapy (cCRT) followed by du
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f6d1fda6710d54e8367b9ea4c5f849ec
https://doi.org/10.1200/jco.2020.38.15_suppl.2069
https://doi.org/10.1200/jco.2020.38.15_suppl.2069
Autor:
Helmneh M. Sineshaw, Xuesong Han, Brian S. Seal, Jingxuan Zhao, Candice Yong, Stephen G. Chun, Zhiyuan Zheng, Doris Makari, Ramesh Rengan, Charles B. Simone
Publikováno v:
Journal of Clinical Oncology. 38:7043-7043
7043 Background: Concurrent chemoradiation therapy (cCRT) has been shown to improve survival outcomes among inoperable stage III non-small cell lung cancer (NSCLC) patients compared to sequential CRT (sCRT) and single-modality therapy in clinical tri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3a1cdd7f06bb9982a4752dd2de228e47
https://doi.org/10.1200/jco.2020.38.15_suppl.7043
https://doi.org/10.1200/jco.2020.38.15_suppl.7043
Publikováno v:
Infectious Diseases and Therapy
Introduction The American Academy of Pediatrics (AAP) Committee on Infectious Diseases issued updated guidance on respiratory syncytial virus (RSV) prophylaxis in 2014. This report models the potential impact of the new guidance on RSV outcomes in pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::897aad6ceeafef65606b5ae2af19bb67
https://doi.org/10.1007/s40121-015-0097-3
https://doi.org/10.1007/s40121-015-0097-3
Autor:
Caroline Park, Doris Makari, Sophie Biguenet, Lim Kai Toh, Gerard Notario, Colleen Wegzyn, Michael Norton, Kristina Unnebrink
Publikováno v:
Infectious Diseases and Therapy
Introduction Lower respiratory tract infection (LRTI) is the leading cause of infant mortality globally in post-neonatal infants (i.e., 28–364 days of age). Respiratory syncytial virus (RSV) is the most commonly identified pathogen for infant LRTI
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::88ed42c408414d062c754c89951af99d
https://doi.org/10.1007/s40121-014-0046-6
https://doi.org/10.1007/s40121-014-0046-6
Publikováno v:
Infectious Diseases and Therapy
Objective To assess the pharmacokinetics and safety of liquid palivizumab compared with lyophilized palivizumab. Methods This phase 2, randomized, double-blind crossover study included premature infants aged ≤6 months born ≤35 weeks gestational a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93c722c9787db365f6f32b3c9f802574
http://europepmc.org/articles/PMC4269619
http://europepmc.org/articles/PMC4269619
Autor:
Jeffrey P. Gregg, Terence W. Friedlander, Andrew Bernstein, Piyush K. Agarwal, Yair Lotan, Marija Tesic-Schnell, Petros Grivas, Joshua J. Meeks, Alicia K. Morgans, Daniel M. Geynisman, Doris Makari
Publikováno v:
Cancer Research. 79:CT178-CT178
Background: Treatments for 1L advanced, unresectable, or metastatic UC include platinum-based chemotherapy, immune checkpoint blockade, or clinical trial enrollment. Not all patients benefit from, or are eligible for, specific therapies due to comorb
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6c70cfb9a5299d342a1adc81400030a6
https://doi.org/10.1158/1538-7445.am2019-ct178
https://doi.org/10.1158/1538-7445.am2019-ct178
Autor:
Ashok Kumar Gupta, Guru Sonpavde, Robert Dreicer, Daniel Hennessy, Dean F. Bajorin, Guenter Niegisch, Sandy Srinivas, Noah M. Hahn, Matthew D. Galsky, Doris Makari, Shaad Essa Abdullah, Thomas Powles, Gregory R. Pond, Petros Grivas, Juliane Manitz, Chen Gao, Jonathan E. Rosenberg, Andrea B. Apolo, Andrea Necchi
Publikováno v:
Journal of Clinical Oncology. 37:4552-4552
4552 Background: A prognostic model for overall survival (OS) of metastatic urothelial carcinoma (mUC) was previously reported in the setting of post-platinum atezolizumab (Pond GR, GU ASCO 2018). This model was limited by employing only atezolizumab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::da5db9e74190d4b9a79d505dc06f5f79
https://doi.org/10.1200/jco.2019.37.15_suppl.4552
https://doi.org/10.1200/jco.2019.37.15_suppl.4552